Can cognitive technology assist with melanoma identification?
29 June 2016
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology – sometimes called ‘artificial intelligence’.
Melanoma Institute Australia operates the world’s largest melanoma research and treatment facility, and controls the largest melanoma research database in the world. “Research that enables the earlier detection of melanoma is likely to save more lives in the future,” says Professor Graham Mann, Research Director at Melanoma Institute Australia. “The five-year survival rate for melanoma is only 64 percent once the disease reaches the lymph nodes. However this rises to 95 percent if detected before then. Diagnosing melanoma with the naked eye is only about 60 percent accurate, but dermoscopy can lift that to over 80 percent. Research using automated analysis of images could provide the next gain in accuracy, especially where dermoscopy is hard to access.”
Using advanced visual analytics IBM Research will conduct retrospective analysis on de-identified data, which will include access to more than one million images as well as text based clinical notes in an effort to improve the accuracy of its machine learning algorithms. IBM’s cognitive technology would aim to learn to understand skin cancers such as melanoma, basal cell carcinoma and squamous cell carcinoma using lower resolution clinical images, with a goal of similar accuracy to what can be achieved with dermoscopy images.
Dr. Joanna Batstone, Vice President and Lab Director, IBM Research – Australia said, “Cognitive computing has the ability to process vast amounts of complex data including images and text very quickly, something that isn’t possible by current manual methods. Another major benefit of the self-learning technology is that it improves as more and more data is fed into it. This initiative could inform future research and, potentially, the development of offerings that could have enormous implications for both the Australian public and the health system.”
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.